What is LY2835219

LY2835219 is a new and innovative cancer drug that has shown promising results in treating various types of cancer. it is an orally effective inhibitor of cyclin dependent kinase (CDK) that targets the CDK4 (cyclinD1) and CDK6 (cyclinD3) cell cycle pathways and has potential anti-tumor activity. it specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in the early ChemicalbookG1 phase. Inhibiting Rb phosphorylation, preventing CDK - mediated G1-S phase transition, resulting in cell cycle arrest in G1 phase, inhibiting DNA synthesis, and inhibiting cancer cell growth. Over expression of serine/threonine kinase CDK4/6 in certain types of cancer leads to uncontrolled cell cycle regulation.

It functions by slowing down cancer cell growth and preventing the proliferation of cancer cells through the inhibition of CDK4/6 activity. This results in better outcomes for patients including improved progression-free survival and potentially even longer overall survival.

Abemaciclib ly2835219 has shown to be well-tolerated by patients, with common side effects being manageable such as diarrhea, fatigue, and nausea. The drug's efficacy has been demonstrated in clinical trials showing an impressive improvement in progression-free survival and response rates.

In summary, it is an innovative cancer drug that has shown promising results in treating various types of cancer, specifically hormone receptor-positive and HER2-negative advanced breast cancer. The drug targets and inhibits CDK4/6, resulting in better outcomes for patients. With the potential to improve overall survival in patients with advanced forms of cancer, Abemaciclib represents a significant advance in cancer treatment.

Basic Information

Product Name: LY2835219; Abemaciclib mesylate

CAS: 1231930-82-7

MF:C28H36F2N8O3S

MW:602.71

MDL No.:MFCD25562906

Appearance: Off-white solid

Purity: 99%+

Package: 1g; 5g;100g

MOQ: 1g

Origin: China

Package: 1g; 5g; 10g

Used: lab research

Stability: Stable

Delivery Time: 3-7days

Structural formula:

Technical Specification:

Function:

Abemaciclib ly2835219 is a drug used in the treatment of breast cancer. It works as a cyclin-dependent kinase (CDK) inhibitor, specifically targeting CDK4 and CDK6. These two proteins promote cell growth and division, which is why they are often over expressed in breast cancer cells. By inhibiting CDK4 and CDK6, it slows down the growth and division of breast cancer cells.

it is often used in combination with other drugs, such as hormonal therapies or other CDK inhibitors, to provide maximum benefit to patients. It is effective in both pre- and post-menopausal women with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Clinical studies have shown that ly2835219 can significantly prolong the progression-free survival of patients with metastatic breast cancer. In one study, the drug increased progression-free survival from 9.3 months to 16.4 months when used in combination with fulvestrant, a hormonal therapy. This represents a significant improvement in the treatment of advanced breast cancer.

Abemaciclib is taken orally, usually in the form of a tablet. It is generally well-tolerated, with fatigue and diarrhea being the most common side effects. Other side effects may include nausea, vomiting, and decreased appetite.

In conclusion, it is an important new weapon in the fight against breast cancer. It works by inhibiting CDK4 and CDK6, which are proteins that promote cell growth and division. With its ability to prolong progression-free survival in patients with advanced breast cancer, it is a valuable addition to the arsenal of drugs used in breast cancer treatment.

Application:

Abemaciclib mesylate is a targeted therapy drug that is used to treat advanced breast cancer. This drug belongs to a class of drugs known as CDK4/6 inhibitors which works by blocking the activity of certain proteins that promote the growth and division of cancer cells.

This medication is administered orally and is available in tablet form. It is typically used in combination with other cancer treatments such as hormonal therapy and chemotherapy. It can be used to treat hormone receptor-positive and HER2-negative breast cancer that has spread to other parts of the body and is unresponsive to other treatments.

Its recommended dosage varies based on the patient's body weight and other factors such as overall health and drug toler ability. Patients should take the medication as directed by their healthcare provider and avoid missing doses.

Common side effects of Abemaciclib include diarrhea, fatigue, nausea, vomiting, and decreased appetite. Patients should inform their healthcare provider immediately if they experience any symptoms of an allergic reaction such as rash, swelling, or difficulty breathing.

It has been shown to be effective in slowing the progression of advanced breast cancer in clinical trials. It is a promising treatment option for patients with invasive metastatic breast cancer who have not responded to other treatments.

In conclusion, it is a targeted therapy drug that is used to treat advanced breast cancer. This medication is used in combination with other cancer treatments and works by blocking the activity of certain proteins that promote the growth and division of cancer cells. Although it may cause side effects, it has shown promising results in clinical trials and is a valuable treatment option for patients with invasive metastatic breast cancer.

Our Advantage

Rich experience: we have 13 Years of professional experience;

Customers all over the world: sell to more than 100 countries;

Provide diversified products: the products have been applied to all major international brands in the fields of drugs, dietary supplements, cosmetics, animal nutrition and functional food.

Price advance: low MOQ with competitive price;

Quality certification: ISO; Halal; Kosher certified

After-sales service: Professional team 7*24 hours customer service.

In conclusion

In summary, Xi'an Yihui company as a professional LY2835219 produced manufacturer, has strong technical strength and advanced production equipment, and is committed to providing customers with high-quality, efficient, and reliable raw materials.

if you need it, pls feel free to contact us at any time. we will reply you asap.

Our contact information:

E-mail: sales@yihuipharm.com
Tel: 0086-29-89695240
WeChat or WhatsApp: 0086-17792415937